We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

By LabMedica International staff writers
Posted on 02 Jun 2023
Print article
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising sample preparation, incubation, washing, and mounting of slides as well as image acquisition and analysis.

EUROIMMUN (Lübeck, Germany) has introduced the UNIQO 160 (CE-IVDR automated IIFT system, a unique benchtop device that combines a fully automated processing system with a high-quality microscope and can be seamlessly integrated into existing diagnostics laboratory workflows. The device boasts the capability to process 160 primary samples and 18 slides per run, while automatically identifying individual samples, reagents, and slides using barcode recognition. This ensures a high level of reliability and traceability of both materials and samples. Additionally, the UNIQO 160 applies a mounting medium and a cover glass for incubated slides to prevent them from drying out, which is a crucial step for achieving high-quality fluorescence images.

The UNIQO 160 generates brilliant fluorescence images using its optical system's autofocus feature and three automatically interchangeable objectives (4x, 10x, 20x). The captured images are then relayed to the system's EUROLabOffice 4.0 middleware for evaluation. Ideal for medium-throughput laboratories, the UNIQO 160 is the latest addition to EUROIMMUN's range of automated laboratory solutions, joining the likes of the EUROPattern Microscope Live, EUROLabWorkstation IFA, and Sprinter XL systems. The UNIQO 160 is also expected to be compatible with the forthcoming EUROPattern Classifier, a software platform that employs cutting-edge pattern classification using artificial intelligence to assist in the final evaluation and suggest analytical results.

“Traditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,” said Dr. Bianca Huth, chief technology officer of EUROIMMUN. “The design of the UNIQO 160 system and technologies built into it alleviate laboratories of many common challenges by reducing hands-on time and creating efficiencies through end-to-end automation.”

Related Links:
EUROIMMUN 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.